IPM Take
The ADA 2026 message is clear: cardiometabolic medicine is entering its combination era. The next generation of therapies is not simply trying to lower A1C or reduce body weight. It is trying to change the biology of diabetes, obesity, liver disease and cardiovascular risk at the same time. That could be clinically powerful, but it will also create hard policy questions. If these therapies reach approval, payers and health systems will need to decide who qualifies first, which outcomes matter most, and whether access should be based on weight, diabetes control, liver disease, cardiovascular risk, or a combination of all four.
Executive Summary
At the 2026 American Diabetes Association Scientific Sessions, several phase 3 trial programmes reported positive findings for next-generation cardiometabolic therapies. CagriSema, a combination of cagrilintide and semaglutide, showed improvements in A1C, body weight, cardiometabolic parameters and beta-cell function across the REIMAGINE trials in adults with type 2 diabetes. Retatrutide, a triple GIP, GLP-1 and glucagon receptor agonist, demonstrated major weight loss and glycaemic improvements in type 2 diabetes and obesity trials. Survodutide, a glucagon/GLP-1 receptor dual agonist, reduced body weight and liver fat in obesity and MASLD studies. Together, the data signal a shift towards multi-pathway treatment strategies in cardiometabolic disease.
Why it matters
- Clinicians: Treatment choices may increasingly depend on patient phenotype, including diabetes stage, obesity severity, liver disease, cardiovascular risk and treatment goals.
- Payers / HTA bodies: Future assessments will need to look beyond A1C and weight loss and consider broader cardiometabolic, liver and quality-of-life outcomes.
- Industry / innovation partners: The competitive field is moving towards multi-agonist and combination therapies with differentiated outcome claims.
- Patients: New therapies may offer broader health benefits, but access could become more complex if eligibility is tied to multiple conditions and risk markers.
For years, diabetes drug development had a fairly simple hierarchy. → Lower glucose, reduce weight, and avoid hypoglycaemia.
ADA 2026 suggests that hierarchy is changing.
The newest cardiometabolic therapies are now being tested on a much wider set of outcomes: A1C, body weight, liver fat, cardiovascular risk markers, sleep apnoea, osteoarthritis pain, beta-cell function and broader metabolic health.
That shift matters because type 2 diabetes is rarely just a glucose disorder. It is usually part of a wider metabolic syndrome involving obesity, insulin resistance, fatty liver disease, hypertension, dyslipidaemia and cardiovascular risk.
The REIMAGINE trials placed CagriSema at the centre of this new treatment logic. By combining an amylin analogue with semaglutide, the therapy aims to target complementary pathways affecting glucose regulation, appetite and weight. Across the phase 3 programme, ADA presenters reported superior A1C and weight reductions compared with placebo and, in REIMAGINE 2, compared with the individual components.
Retatrutide pushed the field further.
As a triple GIP, GLP-1 and glucagon receptor agonist, it is being developed as a multi-hormone therapy for obesity and type 2 diabetes. In TRANSCEND-T2D-1, presenters reported nearly 2% A1C reduction, substantial weight loss and improvements in systolic blood pressure, non-HDL cholesterol and triglycerides. In TRIUMPH-1, retatrutide produced major weight reductions and improvements in obesity-related complications, including sleep apnoea and knee osteoarthritis outcomes.
Survodutide added another dimension.
The glucagon/GLP-1 dual agonist showed significant effects on body weight and liver fat in phase 3 obesity and MASLD studies. That is important because metabolic dysfunction-associated steatotic liver disease is becoming one of the central comorbidities in cardiometabolic medicine, and one of the hardest to manage at population level.
Taken together, the ADA 2026 data point towards a new competitive frontier.
The question is no longer only which drug produces the greatest weight loss. The question is which therapy produces the most meaningful metabolic reset, and in which patient group.
That creates a personalised medicine challenge.
Some patients may need stronger glycaemic control. Others may need liver-directed benefit. Others may need weight loss linked to obstructive sleep apnoea, osteoarthritis, cardiovascular risk or early diabetes progression. A single BMI or A1C threshold may not be enough to guide future treatment decisions.
The policy challenge is just as large.
If multi-agonist therapies reach the market with broad cardiometabolic claims, payers will face pressure to fund them across overlapping indications: diabetes, obesity, MASLD and cardiovascular prevention. Without clear prioritisation, access could become messy, unequal and politically contested.
For IPM, the ADA 2026 signal is not simply that new drugs are working.
It is that cardiometabolic care is becoming more complex, more multi-system and more personalised. Health systems built around single-disease reimbursement categories may struggle to keep up.
